These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2566199)

  • 41. Negative and deficit symptoms in schizophrenia do respond to neuroleptics.
    Goldberg SC
    Schizophr Bull; 1985; 11(3):453-6. PubMed ID: 2863872
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
    Pecknold JC
    J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Psychotropic drugs and depressive syndrome in schizophrenia.
    Planansky K; Johnston R
    Psychiatr Q; 1980; 52(3):214-21. PubMed ID: 6106954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atrophic and static (neurodevelopmental) schizophrenic psychoses: premorbid functioning, symptoms and neuroleptic response.
    Garver DL; Nair TR; Christensen JD; Holcomb J; Ramberg J; Kingsbury S
    Neuropsychopharmacology; 1999 Jul; 21(1):82-92. PubMed ID: 10379522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Viewpoint of schizophrenic patients: a European survey].
    Courtet P
    Encephale; 2001; 27(1):28-38. PubMed ID: 11294036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The meaning and management of neuroleptic medication: a study of patients with a diagnosis of schizophrenia.
    Rogers A; Day JC; Williams B; Randall F; Wood P; Healy D; Bentall RP
    Soc Sci Med; 1998 Nov; 47(9):1313-23. PubMed ID: 9783874
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Sequence in prescribing neuroleptics: a therapeutic alternative in refractory schizophrenia?].
    Allouche G; Joober R; Vanelle JM; Brochier T; Olié JP
    Encephale; 1994; 20(6):777-80. PubMed ID: 7875112
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroleptics reverse attention asymmetries in schizophrenic patients.
    Tomer R; Flor-Henry P
    Biol Psychiatry; 1989 Apr; 25(7):852-60. PubMed ID: 2566334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Neuroleptic treatment and neurological soft signs in schizophrenic patients].
    Mechri A; Slama H; Chebel S; Mandhouj O; Gaha L
    Therapie; 2007; 62(5):449-53. PubMed ID: 18206107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects.
    Gupta S; Andreasen NC; Arndt S; Flaum M; Schultz SK; Hubbard WC; Smith M
    Am J Psychiatry; 1995 Feb; 152(2):191-6. PubMed ID: 7840351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Neuroleptic modification of basic schizophrenic disorders].
    Heim M; Morgner J
    Psychiatr Neurol Med Psychol (Leipz); 1987 May; 39(5):274-80. PubMed ID: 2888144
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The relationship of symptomatology and medication to electrodermal activity in schizophrenia.
    Green MF; Nuechterlein KH; Satz P
    Psychophysiology; 1989 Mar; 26(2):148-57. PubMed ID: 2567035
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment.
    Meltzer HY; Thompson PA; Lee MA; Ranjan R
    Neuropsychopharmacology; 1996 Mar; 14(3 Suppl):27S-33S. PubMed ID: 8866741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroleptic treatment is an unlikely cause of elevated dopamine in thalamus of schizophrenic subjects.
    Oke AF; Putz C; Adams RN; Bird ED
    Psychiatry Res; 1992 Dec; 45(4):203-8. PubMed ID: 1363335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroleptics, dopamine, and schizophrenia.
    Pickar D
    Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Discontinuation of antipsychotic drugs in chronic schizophrenic patients. II. Psychological and psychopathological test differences between patients with and without relapse].
    Woggon B; Bickel P; Schnyder B
    Int Pharmacopsychiatry; 1979; 14(5):278-93. PubMed ID: 43849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The treatment response scale: a retrospective method of assessing response to neuroleptics.
    Csernansky JG; Yesavage JA; Maloney W; Kaplan J
    Am J Psychiatry; 1983 Sep; 140(9):1210-3. PubMed ID: 6137150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.